VTRS - Viatris Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Canonsburg,
United States
Type: Equity
VTRS price evolution
VTRS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $917.2 | $1014.6 | $991.9 | |
| Short term investments | ||||
| Net receivables | $3717.4 | $3566.9 | $3632 | $3700.4 |
| Inventory | $4084.6 | $3942.1 | $3823.2 | $3469.7 |
| Total current assets | $11307.7 | $11792.1 | $12923.5 | $12976.1 |
| Long term investments | ||||
| Property, plant & equipment | $2944.5 | $2662.6 | $2950.3 | $2759.6 |
| Goodwill & intangible assets | $27744.9 | $28827.2 | $29048.2 | |
| Total noncurrent assets | $33537.9 | $34420.2 | $34709.4 | |
| Total investments | ||||
| Total assets | $44754.1 | $45330 | $47343.7 | $47685.5 |
| Current liabilities | ||||
| Accounts payable | $1242.2 | $1957.5 | $1584 | $1938.2 |
| Deferred revenue | ||||
| Short long term debt | $2367.4 | $1898.1 | $1943.4 | |
| Total current liabilities | $7512.4 | $7709.2 | $7759.9 | $7777.4 |
| Long term debt | $14303.4 | $14731.2 | $16072.5 | $16188.1 |
| Total noncurrent liabilities | $18100.8 | $19569.5 | $19440.7 | |
| Total debt | $17098.6 | $17970.6 | $18131.5 | |
| Total liabilities | $24961.7 | $25810 | $27329.4 | $27218.1 |
| Shareholders' equity | ||||
| Retained earnings | $4082 | $4133.9 | $4607.5 | $4639.7 |
| Other shareholder equity | -$2685.7 | -$2975.2 | -$2939.6 | -$2747.4 |
| Total shareholder equity | $19520 | $20014.3 | $20467.4 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $991.9 | $1259.9 | $701.2 | $844.4 |
| Short term investments | $84.9 | |||
| Net receivables | $3700.4 | $3814.5 | $4266.4 | $4843.8 |
| Inventory | $3469.7 | $3519.5 | $3977.7 | $5471.9 |
| Total current assets | $12976.1 | $10635.4 | $10902.9 | $12867.5 |
| Long term investments | $47.9 | |||
| Property, plant & equipment | $2759.6 | $3283.8 | $3188.6 | $3459.9 |
| Goodwill & intangible assets | $29048.2 | $33032.9 | $38247.9 | $42030.2 |
| Total noncurrent assets | $34709.4 | $39386.8 | $43939.9 | $48685.5 |
| Total investments | ||||
| Total assets | $47685.5 | $50022.2 | $54842.8 | $61553 |
| Current liabilities | ||||
| Accounts payable | $1938.2 | $1158 | $1657.4 | $1904.2 |
| Deferred revenue | ||||
| Short long term debt | $1943.4 | $1259.1 | $3370.5 | $3409.4 |
| Total current liabilities | $7777.4 | $6746.2 | $9884.4 | $10562.9 |
| Long term debt | $16188.1 | $18015.2 | $19717.1 | $22429.2 |
| Total noncurrent liabilities | $19440.7 | $22203.7 | $24465.7 | $28036 |
| Total debt | $18131.5 | $19274.3 | $23087.6 | $25838.6 |
| Total liabilities | $27218.1 | $28949.9 | $34350.1 | $38598.9 |
| Shareholders' equity | ||||
| Retained earnings | $4639.7 | $5175.6 | $3688.8 | $5361.2 |
| Other shareholder equity | -$2747.4 | -$2758.9 | -$1744.3 | -$858 |
| Total shareholder equity | $20467.4 | $21072.3 | $20492.7 | $22954.1 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3751.2 | $3796.6 | $3663.4 | $3837.3 |
| Cost of revenue | $2351.2 | $2159.4 | $2240.8 | |
| Gross Profit | $1605.9 | $1445.4 | $1504 | $1596.5 |
| Operating activities | ||||
| Research & development | $204.1 | $199.7 | $202.8 | |
| Selling, general & administrative | $1358 | $1017.5 | $1605.8 | |
| Total operating expenses | $1066.3 | $1685.3 | $1300.1 | $2051 |
| Operating income | -$239.9 | $203.9 | -$454.5 | |
| Income from continuing operations | ||||
| EBIT | -$246 | $343 | -$714.1 | |
| Income tax expense | -$4.3 | -$65.4 | $90.7 | -$89.4 |
| Interest expense | -$145.6 | $145.8 | $138.4 | $140.9 |
| Net income | ||||
| Net income | $94.8 | -$326.4 | $113.9 | -$765.6 |
| Income (for common shares) | -$326.4 | $113.9 | -$765.6 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15426.9 | $16262.7 | $17886.3 | $11946 |
| Cost of revenue | $8988.3 | $9765.7 | $12310.8 | $8149.3 |
| Gross Profit | $6438.6 | $6497 | $5575.5 | $3796.7 |
| Operating activities | ||||
| Research & development | $805.2 | $662.2 | $751.1 | $555.1 |
| Selling, general & administrative | $4650.1 | $4179.1 | $4529.2 | $3344.6 |
| Total operating expenses | $5672.4 | $4882.1 | $5609.5 | $4007.5 |
| Operating income | $766.2 | $1614.9 | -$34 | -$210.8 |
| Income from continuing operations | ||||
| EBIT | $776 | $3405.6 | -$28.2 | -$223.4 |
| Income tax expense | $148.2 | $734.6 | $604.7 | -$51.3 |
| Interest expense | $573.1 | $592.4 | $636.2 | $497.8 |
| Net income | ||||
| Net income | $54.7 | $2078.6 | -$1269.1 | -$669.9 |
| Income (for common shares) | $54.7 | $2078.6 | -$1269.1 | -$669.9 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$326.4 | $113.9 | -$765.6 | |
| Operating activities | ||||
| Depreciation | $786.3 | $691 | $644.4 | |
| Business acquisitions & disposals | $444.6 | -$104.2 | $316.1 | |
| Stock-based compensation | $34.7 | $46.7 | $55.8 | |
| Total cash flows from operations | $379.1 | $614.6 | $479.4 | |
| Investing activities | ||||
| Capital expenditures | -$58.1 | -$49.1 | -$164.9 | |
| Investments | ||||
| Total cash flows from investing | $1969.4 | $375.8 | -$154.3 | $115.8 |
| Financing activities | ||||
| Dividends paid | -$431.5 | -$145.5 | -$142.8 | -$144 |
| Sale and purchase of stock | $0.7 | -$249.4 | $0.6 | |
| Net borrowings | -$801.7 | -$499.7 | ||
| Total cash flows from financing | -$2910.2 | -$847.9 | -$425.6 | -$926.1 |
| Effect of exchange rate | $7.1 | -$4.4 | -$12.4 | $12.7 |
| Change in cash and equivalents | $886.5 | -$97.4 | $22.3 | -$318.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $54.7 | $2078.6 | -$1269.1 | -$669.9 |
| Operating activities | ||||
| Depreciation | $2740.5 | $3027.6 | $4506.5 | $2216.1 |
| Business acquisitions & disposals | -$303.6 | $1950 | $373.7 | $435.8 |
| Stock-based compensation | $180.7 | $116.4 | $111.2 | $79.2 |
| Total cash flows from operations | $2799.6 | $2952.6 | $3016.9 | $1231.8 |
| Investing activities | ||||
| Capital expenditures | -$363 | -$392.2 | -$438.9 | -$240.9 |
| Investments | -$0.3 | -$0.4 | -$57.8 | |
| Total cash flows from investing | -$764.1 | $1520.5 | -$117.8 | -$301.1 |
| Financing activities | ||||
| Dividends paid | -$575.6 | -$581.6 | -$399 | |
| Sale and purchase of stock | -$246.9 | $3.3 | $0.6 | |
| Net borrowings | -$1249.6 | -$3280.1 | -$2099.1 | -$401.3 |
| Total cash flows from financing | -$2301.9 | -$3877.9 | -$3012 | -$605.7 |
| Effect of exchange rate | -$2.5 | -$38.9 | -$30.9 | $33.8 |
| Change in cash and equivalents | -$268.9 | $556.3 | -$143.8 | $358.8 |
News
Fundamentals
| Market cap | $12.89B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.19B |
| Revenue | $15.05B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$883.30M |
| Revenue Q/Q | -4.84% |
| Revenue Y/Y | -2.70% |
| P/E ratio | -14.59 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.86 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.74 |
|---|---|
| ROA | -1.91% |
| ROE | N/A |
| Debt/Equity | 1.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.51 |
| Quick ratio | 0.96 |